Paper Details

  1. Home
  2. Paper Details

Avatrombopag: First Global Approval.

Author: ShirleyMatt

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Avatrombopag is an orally bioavailable thrombopoietin receptor agonist approved for treating thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled for a procedure. This article summarizes the milestones in the development of avatrombopag and its potential applications in other thrombocytopenic disorders.
Paper Details　
Original Abstract of the Article :
Avatrombopag (Doptelet<sup>&#174;</sup>) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40265-018-0949-8

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A New Dawn in Thrombocytopenia Treatment

The treatment of thrombocytopenic disorders, characterized by low platelet counts, is a constant challenge for medical professionals. This research focuses on the groundbreaking development of avatrombopag (Doptelet®), an orally bioavailable, small molecule thrombopoietin receptor agonist. The study highlights the significance of this novel drug, which has been approved for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.

Avatrombopag: A Beacon of Hope for Thrombocytopenia

The approval of avatrombopag marks a significant milestone in the fight against thrombocytopenia. The development of this orally bioavailable drug offers a convenient and potentially more effective treatment option for patients with CLD, a group often facing challenges related to platelet deficiencies. This breakthrough, like a refreshing spring in the desert, offers hope for patients who have previously struggled with managing their condition.

Expanding the Horizons of Thrombocytopenia Treatment

This research signifies a shift in the treatment paradigm for thrombocytopenia. The availability of avatrombopag provides a valuable addition to the therapeutic arsenal, offering a more convenient and potentially safer option for patients. The ongoing research into the use of avatrombopag for other thrombocytopenic disorders further underscores the potential of this drug to revolutionize treatment strategies and improve patient outcomes.

Dr. Camel's Conclusion

Avatrombopag represents a promising addition to the toolbox for treating thrombocytopenia. This novel drug offers a beacon of hope for patients, particularly those with CLD, who have previously struggled with managing their condition. The approval of avatrombopag marks a significant step forward in the quest for effective and patient-centered treatments for thrombocytopenic disorders, a journey as transformative as a desert bloom pushing through the arid sands.
Date :
  1. Date Completed 2019-03-08
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29995177

DOI: Digital Object Identifier

10.1007/s40265-018-0949-8

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.